secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001171843-23-004444
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst principal accounting officer resigns; CFO to serve as interim
----------------------------------------------------------------------

- Michael Jones, Principal Accounting Officer, resigns effective July 7, 2023; will stay as Exec. Director Finance through April 2024.
- Resignation not due to any disagreement on company operations, policies, or practices.
- Board appoints CFO Anthony Doyle as interim Principal Accounting Officer effective July 10, 2023.
- Doyle's compensation unchanged; no family relationships or transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184323004444/0001171843-23-004444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184323004444/f8k_071123.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-004444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer